January 15, 2023
3 min watch
Save
VIDEO: Study results reaffirm anti-VEGF agents work for promoting regression of ROP
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, R.V. Paul Chan, MD, discusses treatment options for pediatric retinal disease and retinopathy of prematurity.
Chan recounts results from the FIREFLEYE study, a randomized clinical trial that compared aflibercept vs. laser for type 1 ROP and aggressive ROP.
“This study was very important because it basically just affirmed what we know, which is that anti-VEGF generally works for promoting regression of disease,” Chan said.
Published by:
Sources/Disclosures
Collapse
Source:
Chan RVP. Treatment of pediatric retina patients in the era of laser and anti-VEGF. Presented at: Hawaiian Eye; Jan. 14-20, 2023; Koloa, Hawaii.
Disclosures:
Chan reports consulting and advising for Alcon and Genentech, and being an owner of and having equity in Siloam Vision.
Read more about